中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
2期
31-33
,共3页
赵峥%杨晓光%苏春勇%马小刚%聂晓进%任利兵
趙崢%楊曉光%囌春勇%馬小剛%聶曉進%任利兵
조쟁%양효광%소춘용%마소강%섭효진%임리병
肺肿瘤%淋巴结%抗肿瘤联合化疗方案%紫杉醇脂质体
肺腫瘤%淋巴結%抗腫瘤聯閤化療方案%紫杉醇脂質體
폐종류%림파결%항종류연합화료방안%자삼순지질체
Lung neoplasms%Lymph nodes%Antineoplastic combined chemotherapy protocols%Paclitaxel liposome
目的 评价非小细胞肺癌术后淋巴结转移应用紫杉醇脂质体与传统紫杉醇化疗的临床近期疗效及不良反应.方法 将68例非小细胞肺癌术后淋巴结转移的患者按随机数字表法分为试验组37例和对照组31例.试验组应用紫杉醇脂质体(135 mg/m2)联合卡铂(300 mg/m2)进行化疗,对照组应用传统紫杉醇(135 mg/m2)联合卡铂(300 mg/m2)进行化疗.比较两组的临床近期疗效及不良反应.结果 68例患者均可评价疗效,试验组完全缓解5例,部分缓解10例,稳定17例,进展5例,有效率40.5％(15/37),临床控制率86.5％(32/37)；对照组完全缓解2例,部分缓解8例,稳定15例,进展6例,有效率32.3％(10/31),临床控制率80.6％(25/31).试验组治疗效果优于对照组,差异有统计学意义(P＜0.05).主要不良反应为骨髓抑制、脱发、肌肉关节酸痛、消化道症状等,无严重过敏反应,试验组低血压、面部潮红、感觉异常、肌肉关节痛、皮疹的发生率低于对照组[0比9.7％(3/31),5.4％(2/37)比19.4％(6/31),10.8％(4/37)比22.6％ (7/31),13.5％(5/37)比38.7％(12/31),5.4％(2/37)比25.8％(8/31)],差异有统计学意义(P＜ 0.01或＜0.05).结论 对于非小细胞肺癌术后淋巴结转移患者,紫杉醇脂质体有效率较传统紫杉醇药物高,而且紫杉醇脂质体出现不良反应者明显减少,药物耐受性高.
目的 評價非小細胞肺癌術後淋巴結轉移應用紫杉醇脂質體與傳統紫杉醇化療的臨床近期療效及不良反應.方法 將68例非小細胞肺癌術後淋巴結轉移的患者按隨機數字錶法分為試驗組37例和對照組31例.試驗組應用紫杉醇脂質體(135 mg/m2)聯閤卡鉑(300 mg/m2)進行化療,對照組應用傳統紫杉醇(135 mg/m2)聯閤卡鉑(300 mg/m2)進行化療.比較兩組的臨床近期療效及不良反應.結果 68例患者均可評價療效,試驗組完全緩解5例,部分緩解10例,穩定17例,進展5例,有效率40.5％(15/37),臨床控製率86.5％(32/37)；對照組完全緩解2例,部分緩解8例,穩定15例,進展6例,有效率32.3％(10/31),臨床控製率80.6％(25/31).試驗組治療效果優于對照組,差異有統計學意義(P＜0.05).主要不良反應為骨髓抑製、脫髮、肌肉關節痠痛、消化道癥狀等,無嚴重過敏反應,試驗組低血壓、麵部潮紅、感覺異常、肌肉關節痛、皮疹的髮生率低于對照組[0比9.7％(3/31),5.4％(2/37)比19.4％(6/31),10.8％(4/37)比22.6％ (7/31),13.5％(5/37)比38.7％(12/31),5.4％(2/37)比25.8％(8/31)],差異有統計學意義(P＜ 0.01或＜0.05).結論 對于非小細胞肺癌術後淋巴結轉移患者,紫杉醇脂質體有效率較傳統紫杉醇藥物高,而且紫杉醇脂質體齣現不良反應者明顯減少,藥物耐受性高.
목적 평개비소세포폐암술후림파결전이응용자삼순지질체여전통자삼순화료적림상근기료효급불량반응.방법 장68례비소세포폐암술후림파결전이적환자안수궤수자표법분위시험조37례화대조조31례.시험조응용자삼순지질체(135 mg/m2)연합잡박(300 mg/m2)진행화료,대조조응용전통자삼순(135 mg/m2)연합잡박(300 mg/m2)진행화료.비교량조적림상근기료효급불량반응.결과 68례환자균가평개료효,시험조완전완해5례,부분완해10례,은정17례,진전5례,유효솔40.5％(15/37),림상공제솔86.5％(32/37)；대조조완전완해2례,부분완해8례,은정15례,진전6례,유효솔32.3％(10/31),림상공제솔80.6％(25/31).시험조치료효과우우대조조,차이유통계학의의(P＜0.05).주요불량반응위골수억제、탈발、기육관절산통、소화도증상등,무엄중과민반응,시험조저혈압、면부조홍、감각이상、기육관절통、피진적발생솔저우대조조[0비9.7％(3/31),5.4％(2/37)비19.4％(6/31),10.8％(4/37)비22.6％ (7/31),13.5％(5/37)비38.7％(12/31),5.4％(2/37)비25.8％(8/31)],차이유통계학의의(P＜ 0.01혹＜0.05).결론 대우비소세포폐암술후림파결전이환자,자삼순지질체유효솔교전통자삼순약물고,이차자삼순지질체출현불량반응자명현감소,약물내수성고.
Objective To evaluate the difference of clinical short-term effect and adverse reaction between paclitaxel liposome and paclitaxel in non-small cell lung cancer patients with lymph node metastasis after pulmonary resection.Methods Sixty-eight patients after pulmonary resection were divided into two groups by random digits table method,37 patients in experimental group with paclitaxel liposome (135mg/m2) combined with carboplatin (CBP) at 300 mg/m2 in chemotherapy,and 31 patients in control group with paclitaxel (135 mg/m2) combined with CBP at 300 mg/m2 in chemotherapy.Results All patients were evaluable.In experimental group,5 patients had complete remission,10 patients had partial remission,17patients were stable,5 patients' condition aggravated,the total effective rate was 40.5％(15/37),clinical control rate was 86.5％ (32/37).In control group,2 patients had complete remission,8 patients had partial remission,15 patients were stable,6 patients' condition aggravated,the total effective rote was 32.3％(10/31),clinical control rate was 80.6％(25/31).The treatment effectiveness in experimental group was significantly higher than that in control group (P ＜ 0.05).The main adverse reaction included marrow suppression,hair loss,muscle and joint pain and gastrointestinal symptom,there was no serious hypersensitivity.The rate of hypotension,face flushing,paresthesia,muscle and joint pain,erythra in experimental group was lower than that in control group [0 vs.9.7％ (3/31),5.4％ (2/37) vs.19.4％ (6/31),10.8％ (4/37) vs.22.6％ (7/31),13.5％ (5/37) vs.38.7％ (12/31),5.4％ (2/37) vs.25.8％ (8/31)] (P ＜0.0 1 or ＜0.05).Conclusion The curative effect rate of paclitaxel liposome is better than paclitaxel in patients with lymph node metastasis after pulmonary resection and with lower incidence of side effects.
